NCT04944953View on ClinicalTrials.gov

"To Compare the Safety and Efficacy of HG-102 With Botox® in the Improvement of Moderate to Severe Glabellar Lines."

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

September 2, 2021

Study Completion Date

December 16, 2021

Conditions
Glabellar Lines
Interventions
DRUG

Botulinum Toxin Type A Injection [Botox]

Single administration, Day 0, 20 units

DRUG

Botulinum toxin type A injection [HG-102]

Single administration, Day 0, 20 units

Trial Locations (1)

05030

Konkuk University Medical Center, Seoul

All Listed Sponsors
lead

Hugel

INDUSTRY